No Data
No Data
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $5
Buy Rating Affirmed for Tenaya Therapeutics Amid Promising TN-201 Data and Financial Stability
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3
William Blair Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
Express News | HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target
Tenaya Therapeutics Announces Late Breaker Presentation Of New Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 At American College Of Cardiology Annual Meeting